A fresh licensing deal tidies up years of work between the two companies.
ApexOnco Front Page
Recent articles
And that could affect the drug's third-line accelerated approval.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
BNT329 enters the clinic, as do four other new ADCs.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
